TG Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -1.90%73.341.0%$1909.68m
AMGNAmgen, Inc. -2.10%198.481.3%$884.40m
REGNRegeneron Pharmaceuticals, Inc. -0.96%483.602.6%$825.79m
BIIBBiogen, Inc. -1.95%310.221.5%$744.42m
VRTXVertex Pharmaceuticals, Inc. -3.46%229.731.9%$567.98m
MRNAModerna, Inc. 0.30%30.040.0%$537.25m
ILMNIllumina, Inc. -2.92%265.153.5%$458.46m
ALXNAlexion Pharmaceuticals, Inc. -1.02%88.872.0%$283.11m
AAgilent Technologies, Inc. -2.81%69.611.6%$222.18m
EXASEXACT Sciences Corp. -3.82%55.7921.0%$186.98m
INCYIncyte Corp. -0.81%72.642.5%$175.16m
SGENSeattle Genetics, Inc. -1.34%113.836.1%$167.23m
BMRNBioMarin Pharmaceutical, Inc. 0.41%84.854.3%$167.06m
NVAXNovavax, Inc. 8.44%14.73114.7%$135.40m
ALNYAlnylam Pharmaceuticals, Inc. -0.98%107.788.7%$101.42m

Company Profile

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.